欢迎您访问《中华养生保健》官方网站!

中华养生保健 ›› 2024, Vol. 42 ›› Issue (9): 28-31.

• 中医诊疗 • 上一篇    下一篇

血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭患者的应用效果及对神经内分泌因子的影响

刘燕, 侯聪   

  1. 北京市垂杨柳医院老年科,北京,100022
  • 出版日期:2024-05-01 发布日期:2024-04-23
  • 作者简介:刘燕(1986—),女,汉族,籍贯:湖北省黄冈市,硕士研究生,主治医师,研究方向:老年病相关。

The Application Effect of Xuezhikang Capsule Combined with Pravastatin Sodium Tablets on Elderly Patients with Chronic Heart Failure after Acute Myocardial Infarction and Its Impact on Neuroendocrine Factors

LIU Yan, HOU Cong   

  1. Department of Geriatric, Beijing Chuiyangliu Hospital, Beijing, 100022, China
  • Online:2024-05-01 Published:2024-04-23

摘要: 目的 探讨血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭患者的应用效果及对神经内分泌因子的影响。方法 选取2022年6月—2023年4月北京市垂杨柳医院收治的80例急性心肌梗死后慢性心力衰竭患者作为对象进行研究,应用抽签法将其分为三组,即对照组(n=30)、观察A组(n=25)和观察B组(n=25)。给予对照组患者常规治疗,观察A组患者在对照组治疗的基础上增加普伐他汀钠片口服,观察B组患者在观察A组基础上增加血脂康胶囊口服。对比三组患者临床疗效,血浆B型利钠肽(BNP)、血浆肾素(PRA)、醛固酮(ALD)以及血管紧张素Ⅱ(AngⅡ)相关神经内分泌因子水平与左心室射血分数(LVEF)、左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)相关心功能指标变化。结果 观察B组总有效率明显高于对照组和观察A组,观察A组高于对照组(P<0.05);治疗后三组患者BNP、PRA、ALD、AngⅡ水平均降低,且观察B组低于对照组和观察A组,观察A组低于对照组(P<0.05);治疗后三组患者LVEF升高,观察B组高于对照组和观察A组,观察A组高于对照组,LVESV、LVEDV降低,观察B组低于对照组和观察A组,观察A组低于对照组(P<0.05)。结论 血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭具有显著治疗效果,且能够降低神经内分泌因子水平,提升心功能,值得临床应用。

关键词: 血脂康胶囊, 普伐他汀钠片, 急性心肌梗死, 慢性心力衰竭, 神经内分泌因子

Abstract: Objective To explore the application effect of Xuezhikang Capsule combined with pravastatin sodium tablets on elderly patients with chronic heart failure after acute myocardial infarction and its impact on neuroendocrine factors. Methods Eighty patients with chronic heart failure after acute myocardial infarction admitted to Chuiyangliu Hospital in Beijing from June 2022 to April 2023 were selected for study. They were divided into three groups by lot drawing, namely, control group (n=30), observation group A (n=25) and observation group B (n=25). After giving conventional treatment to the control group, observe the patients in group A to add pravastatin sodium tablets on the basis of the control group, and increase the oral administration of Xuezhikang Capsule on the basis of observation group A. The clinical efficacy of the three groups of patients was compared, and the levels of B-type natriuretic peptide (BNP), plasma renin (PRA), Aldosterone (ALD), and angiotensin Ⅱ (Ang Ⅱ) related endocrine factors were compared with the changes of left ventricular Ejection fraction (LVEF), left ventricular end systolic volume (LVESV), and left ventricular end diastolic volume (LVEDV) related cardiac function indexes. Results The total effective rate of Group B was significantly higher than that of the control group and Group A, and Group A was higher than the control group (P<0.05); After treatment, the levels of BNP, PRA, ALD, and Ang II in the three groups of patients decreased, and the observation group B was lower than the control group and observation group A, while the observation group A was lower than the control group (P<0.05); After treatment, the LVEF of the three groups of patients increased, and Group B was observed to be higher than the control group and Group A. Group A was observed to be higher than the control group, while LVESV and LVEDV decreased. Group B was observed to be lower than the control group and Group A, and Group A was observed to be lower than the control group (P<0.05). Conclusion The combination of Xuezhikang Capsule and Pravastatin Sodium Tablets has a significant therapeutic effect on elderly patients with chronic heart failure after acute myocardial infarction, and can reduce the levels of neuroendocrine factors and improve heart function, which is worthy of clinical application.

Key words: Xuezhikang Capsule, pravastatin sodium tablets, acute myocardial infarction, chronic heart failure, neuroendocrine factors

中图分类号: